神经科

订阅

MedSci主页 / 所有栏目 / 神经科

第14届阿尔茨海默症和帕金森国际会议：Eisai将公布其一系列在研药物的临床试验结果

2019-03-24 不详 网络

阿尔茨海默症帕金森淀粉样蛋白β
关注

Eisai公司近日宣布，将于3月26日举行的第14届阿尔茨海默症和帕金森国际会议上公布其一系列在研药物的临床试验结果：BAN2401，一种抗淀粉样蛋白β（Aβ）初原纤维抗体，正在进行III期试验；elenbecestat，一种口服选择性BACE1抑制剂，目前正在进行两项III期研究（MISSION AD1 / 2）。

Eisai公司近日宣布，将于3月26日举行的第14届阿尔茨海默症和帕金森国际会议上公布其一系列在研药物的临床试验结果：BAN2401，一种抗淀粉样蛋白β（Aβ）初原纤维抗体，正在进行III期试验；elenbecestat，一种口服选择性BACE1抑制剂，目前正在进行两项III期研究（MISSION AD1 / 2）。

淀粉样蛋白β在器官中不正常的堆积，会造成类淀粉沉积症（amyloidosis）。在许多神经性疾病，如阿尔茨海默症、帕金森氏症中，都可以观察到神经系统中出现大量淀粉样物质的累积沉淀。许多学者相信它可能导致脑部或其他器官退化或功能障碍。


原始出处：

http://www.firstwordpharma.com/node/1630944?tsid=4#axzz5j31eEshK

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1817927, encodeId=e772181e927d3, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 28 08:23:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816904, encodeId=99e71816904d6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Oct 10 05:23:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946729, encodeId=8f981946e29a5, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jan 19 03:23:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470281, encodeId=e00714e0281e0, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Mar 26 01:23:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363475, encodeId=0b473634e5fa, content=向挑战病魔的科研人员致敬！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Mar 24 16:27:52 CST 2019, time=2019-03-24, status=1, ipAttribution=)]
    2019-12-28 12498da4m32(暂无昵称)

    #阿尔茨海#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1817927, encodeId=e772181e927d3, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 28 08:23:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816904, encodeId=99e71816904d6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Oct 10 05:23:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946729, encodeId=8f981946e29a5, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jan 19 03:23:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470281, encodeId=e00714e0281e0, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Mar 26 01:23:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363475, encodeId=0b473634e5fa, content=向挑战病魔的科研人员致敬！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Mar 24 16:27:52 CST 2019, time=2019-03-24, status=1, ipAttribution=)]
    2019-10-10 ms1948154235210413

    #阿尔茨#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1817927, encodeId=e772181e927d3, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 28 08:23:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816904, encodeId=99e71816904d6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Oct 10 05:23:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946729, encodeId=8f981946e29a5, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jan 19 03:23:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470281, encodeId=e00714e0281e0, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Mar 26 01:23:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363475, encodeId=0b473634e5fa, content=向挑战病魔的科研人员致敬！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Mar 24 16:27:52 CST 2019, time=2019-03-24, status=1, ipAttribution=)]
    2020-01-19 ms920641618706883

    #国际会议#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1817927, encodeId=e772181e927d3, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 28 08:23:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816904, encodeId=99e71816904d6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Oct 10 05:23:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946729, encodeId=8f981946e29a5, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jan 19 03:23:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470281, encodeId=e00714e0281e0, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Mar 26 01:23:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363475, encodeId=0b473634e5fa, content=向挑战病魔的科研人员致敬！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Mar 24 16:27:52 CST 2019, time=2019-03-24, status=1, ipAttribution=)]
    2019-03-26 yhj-time

    #阿尔茨海默#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1817927, encodeId=e772181e927d3, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Sat Dec 28 08:23:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1816904, encodeId=99e71816904d6, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Thu Oct 10 05:23:00 CST 2019, time=2019-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1946729, encodeId=8f981946e29a5, content=<a href='/topic/show?id=5c1b41061c6' target=_blank style='color:#2F92EE;'>#国际会议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41061, encryptionId=5c1b41061c6, topicName=国际会议)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=aa5a2500103, createdName=ms920641618706883, createdTime=Sun Jan 19 03:23:00 CST 2020, time=2020-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1470281, encodeId=e00714e0281e0, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Tue Mar 26 01:23:00 CST 2019, time=2019-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=363475, encodeId=0b473634e5fa, content=向挑战病魔的科研人员致敬！！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Mar 24 16:27:52 CST 2019, time=2019-03-24, status=1, ipAttribution=)]
    2019-03-24 坚强007

    向挑战病魔的科研人员致敬！！！

    0

相关资讯

第14届阿尔茨海默症和帕金森国际会议：Aptinyx将介绍NYX-458的临床前数据

Aptinyx是一家临床阶段的生物制药公司，开发用于治疗大脑和神经系统疾病的变革疗法，近日宣布即将在第14届阿尔茨海默症和帕金森国际会议上发表演讲，重点介绍其新型NMDA受体调节剂NYX-458的临床前数据

勃林格殷格翰 BI409306 阿尔茨海默症 2 期试验失败

2 月 9 日，德国勃林格殷格翰（BI）公司表示，公司候选药物 BI409306 用于阿尔茨海默症治疗的 2 期临床研究未能达到疗效终点，公司将不会继续进行 BI409306 用于阿尔茨海默症的继续开发。但公司认为，该药物对精神分裂症还有治疗希望，该公司将把精力集中在进行中的精神分裂症临床试验中。

植入记忆法：或为阿尔茨海默病患者寻回记忆

阿尔茨海默症（Alzheimer）俗称老年痴呆症。其病理为：淀粉样蛋白斑在大脑中累积从而阻碍脑细胞交流信息。患者通常会丧失情节记忆（episodic memory），如记不得刚刚把车停哪儿了、钥匙放哪儿了。遗忘这些日常场景信息无疑给老年人的生活带来极大不便。所幸，据英国《每日电讯报》（The Telegraph）报道，美国有试验性研究表明阿尔茨海默病患者有望恢复记忆，重新记起亲人以及回家的路！“植

“绕开”致病蛋白！预防老年痴呆症的基因疗法试验即将启动

将来有一天，APOE4患者去看医生，一次性注射APOE2，或许就能预防阿尔茨海默症。

Cell Rep：科学家发现一种治疗帕金森的新疗法！或将颠覆神经疾病的治疗

系统清除衰老星形胶质细胞可以预防散发性阿尔茨海默症（代表了95%的人类病例）模型小鼠出现帕金森神经病理和相关症状。这项研究发表在《Cell Reports》上，来自Buck研究所Andersen实验室的研究人员提供了一种针对这种导致数百万美国人行动控制能力下降的、难治愈的恶性神经疾病的新型治疗方案。

由于毒理学发现，Allergan/Sosei公司将延迟阿尔茨海默症新药HTL0018318的临床开发

由于在非人类灵长类动物的研究中意外发现的毒理作用，Allergan和Sosei自愿暂停HTL0018318的临床开发工作。